Hsbc Holdings PLC Increases Holdings in Boston Scientific Corporation $BSX

Hsbc Holdings PLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 3.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,533,722 shares of the medical equipment provider’s stock after purchasing an additional 134,019 shares during the quarter. Hsbc Holdings PLC owned about 0.24% of Boston Scientific worth $150,598,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC increased its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC boosted its stake in shares of Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC increased its holdings in Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC increased its holdings in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BSX shares. Barclays lowered their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. UBS Group dropped their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Canaccord Genuity Group reduced their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Oppenheimer lowered their price target on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating on the stock in a report on Monday, July 27th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 194,522 shares of company stock worth $9,385,210 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 1.7%

Shares of BSX stock opened at $49.86 on Wednesday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The stock’s fifty day moving average price is $46.44 and its 200 day moving average price is $57.14. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market cap of $72.26 billion, a price-to-earnings ratio of 20.19, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.